trending Market Intelligence /marketintelligence/en/news-insights/trending/78IbMMJn8rY5pqjBd9Ek6g2 content esgSubNav
In This List

UK's NICE recommends Celgene pancreatic cancer drug for use in NHS

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


UK's NICE recommends Celgene pancreatic cancer drug for use in NHS

The U.K.'s National Institute for Health and Care Excellence, or NICE, recommended Celgene Corp.'s pancreatic cancer drug Abraxane for routine use in the National Health Service.

Celgene agreed to a confidential price discount to make the drug more cost-effective.

Abraxane can extend the life of pancreatic cancer patients by an average of 2.4 months when added to standard chemotherapy.

The life expectancy of pancreatic cancer patients is up to six months. There are almost 10,000 new cases of pancreatic cancer each year in the U.K.